$MRNS: Marinus Pharmaceuticals announces top-line data from a Phase 2 study to evaluate ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome; primary endpoint was not met - 7:31 AM ET 6/28/16 | Briefing.com - The co announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome. The investigator selected Clinical Global Impression of Improvement, which is a broad scale to assess the overall improvement across the entire Fragile X Syndrome, as the primary endpoint of the study.

Was up big this morning and moved lower and now starting to go higher again.